PLUR

Pluri Inc.

PLUR, USA

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

https://www.pluri-biotech.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PLUR
stock
PLUR

Plurilock Security Inc.'s (CVE:PLUR) Shares Lagging The Industry But So Is The Business simplywall.st

Read more →
PLUR
stock
PLUR

Tech Rally: How strong is RF Industries Ltd stock balance sheet - Weekly Trade Recap & Community Driven Trade Alerts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$12

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-24.39

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

53.98 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-18.21 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,754.43 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 0.92% of the total shares of Pluri Inc.

1.

Renaissance Technologies Corp

(0.3484%)

since

2025/06/30

2.

Citadel Advisors Llc

(0.3232%)

since

2025/06/30

3.

Values First Advisors Inc

(0.154%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(0.0392%)

since

2025/06/30

5.

Fidelity Nasdaq Composite Index

(0.035%)

since

2025/07/31

6.

Citigroup Inc

(0.009%)

since

2025/06/30

7.

Bank of America Corp

(0.0033%)

since

2025/06/30

8.

Wells Fargo & Co

(0.0024%)

since

2025/06/30

9.

Zurcher Kantonalbank

(0.0017%)

since

2025/06/30

10.

Royal Bank of Canada

(0.0016%)

since

2025/06/30

11.

JPMorgan Chase & Co

(0.0016%)

since

2025/06/30

12.

TD Waterhouse Canada Inc

(0.0012%)

since

2025/06/30

13.

UBS Group AG

(0.0008%)

since

2025/06/30

14.

SBI Securities Co Ltd

(0.0006%)

since

2025/06/30

15.

Advisor Group Holdings, Inc.

(0.0006%)

since

2025/06/30

16.

Winch Advisory Services, LLC

(0.0003%)

since

2025/06/30

17.

TFC Financial Management

(0.0002%)

since

2025/06/30

18.

CBIZ Investment Advisory Services, LLC

(0.0001%)

since

2025/06/30

19.

IFP Advisors, LLC

(0%)

since

2025/06/30

20.

Jane Street Group LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.65

EPS Estimate

-0.74

EPS Difference

0.09

Surprise Percent

12.1622%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.